SARC023 January 3, 2024 SARC023 is a Phase I/II Trial of Ganetespib in combination with the mTOR inhibitor sirolimus for patients with recurrent or refractory sarcomas including unresectable or metastatic malignant peripheral nerve sheath tumors. TYPE OF SARCOMA: Unresectable or metastatic sporadic or neurofibromatosis type 1 (NF1) associated MPNSTDRUG: Ganetespib in combination with Sirolimus ACCRUAL STATUS: Completed